Importance of external quality assessment for SARS-CoV-2 antigen detection during the COVID-19 pandemic

Mantke, Oliver Donoso; Corman, Victor M.; Taddei, Francesca; McCulloch, Elaine; Niemeyer, Daniela; Grumiro, Laura; Dirani, Giorgio; Wallace, Paul S.; Drosten, Christian; Sambri, Vittorio

Published in:
Journal of Clinical Virology

DOI:
10.1016/j.jcv.2022.105222

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2022

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):
Mantke, O. D., Corman, V. M., Taddei, F., McCulloch, E., Niemeyer, D., Grumiro, L., Dirani, G., Wallace, P. S., Drosten, C., Sambri, V., & Niesters, H. G. M. (2022). Importance of external quality assessment for SARS-CoV-2 antigen detection during the COVID-19 pandemic. Journal of Clinical Virology, 154, Article 105222. https://doi.org/10.1016/j.jcv.2022.105222

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment.

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Importance of external quality assessment for SARS-CoV-2 antigen detection during the COVID-19 pandemic

Oliver Donoso Mantke a,*, Victor M. Corman b,c, Francesca Taddei d, Elaine McCulloch a,*, Daniela Niemeyer b, Laura Grumiro d, Giorgio Dirani d, Paul S. Wallace a, Christian Drosten b, Vittorio Sambri d, Hubert G.M. Niesters e

a Quality Control for Molecular Diagnostics (QCMD), Glasgow, United Kingdom
b Institute of Virology, Charité-Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany, and German Center for Infection Research (DZIF), Berlin, Germany
c Labor Berlin-Charité Vivantes GmbH, Berlin, Germany
d Unit of Microbiology, The Great Romagna Area Hub Laboratory, Pievesentina di Cesena (FC), Italy
e The University of Groningen, University Medical Center Groningen, Division of Clinical Virology, Department of Medical Microbiology and Infection Prevention, Groningen, the Netherlands

* Corresponding authors at: QCMD, Unit 5, Technology Terrace, Todd Campus, West of Scotland Science Park, Glasgow G20 0XA, Scotland, UK
E-mail addresses: oliverdonoso@qcmd.org (O. Donoso Mantke), elainemcculloch@qcmd.org (E. McCulloch).

https://doi.org/10.1016/j.jcv.2022.105222
Received 23 February 2022; Received in revised form 21 June 2022; Available online 27 June 2022
1386-6532/© 2022 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

ARTICLE INFO

Keywords:
Severe acute respiratory syndrome
Antigen test
COVID-19 testing
Sensitivity
SARS-CoV-2 variants
Quality assurance

ABSTRACT

Background: Antigen testing has become an essential part of fighting the ongoing COVID-19 pandemic. With the continual increase in available tests, independent and extensive comparative evaluations using data from external quality assessment (EQA) studies to evaluate test performance between different users are required.

Objectives: An EQA scheme was established to assess the sensitivity of antigen tests and the potential impact of circulating SARS-CoV-2 strains on their performance.

Study design: Panels were prepared for three challenges in 2021 containing inactivated SARS-CoV-2-positive samples of various genetic strains (including variants of concern, VOCS) at different concentrations, and negative samples. Data was analysed based on qualitative testing results in relation to the antigen test used.

Results: Participants registered for each individual challenge in any combination. In total, 258 respondents from 27 countries worldwide were counted submitting 472 datasets. All core samples were correctly reported by 76.7 to 83.1% at participant level and by 73.5 to 83.8% at dataset level. Sensitivity differences could be shown in viral loads and SARS-CoV-2 strains/variants including the impact on performance by a B.1.1.7-like mutant strain with a deletion in the nucleoprotein gene. Lateral flow rapid antigen tests showed a higher rate of false negatives in general compared with automated point-of-care tests and laboratory ELISA/immunoassays.

Conclusions: EQA schemes can provide valuable data to inform participants about weaknesses in their testing process or methods and support ongoing assay evaluations for regulatory approval or post-market surveillance.

1. Introduction

Reliable SARS-CoV-2 diagnostic assays are an important component for COVID-19 infection and outbreak control. In late 2020/early 2021, the use of antigen tests (laboratory-based and point-of-care (PoC) tests, including lateral flow rapid antigen tests (LFTs)) were integrated into testing strategies to complement molecular detection of SARS-CoV-2 in many countries [1–3]. While nucleic acid amplification tests (NAATs) remain the gold standard for SARS-CoV-2 detection due to high sensitivity and specificity [4], antigen testing has become a diagnostic pillar and essential part of fighting the ongoing pandemic. In case of LFTs, the technology offers the possibility of simple, low-cost, early detection of infectious COVID-19 cases, and can be used for screening or testing in settings which are removed from clinical and laboratory environments (e.g., long-term care facilities, schools, or mobile testing units), especially where NAAT testing capacity is reduced or a rapid test turnaround time is required [5–10].

The number of commercially available antigen tests has increased dramatically [11]. In Europe, 950 CE-marked antigen tests (560 rapid) are currently on the market [12]. With continual increases in available
tests, the number of validation studies has also increased but there are still only a small number of independent extensive comparative evaluations [13-15]. Also, data from external quality assessment (EQA) studies to evaluate the test performance amongst different users are required.

Here, we present the results of an EQA scheme with three challenges to assess the sensitivity of antigen tests and the potential impact of circulating SARS-CoV-2 strains on their performance, introduced in 2021 by Quality Control for Molecular Diagnostics (QCMD, Glasgow, Scotland, UK).

2. Materials and methods

2.1. Sample preparation and composition of panels

Panels for the QCMD SARS-CoV-2 Antigen Testing EQA Study were produced under ISO 13485 manufacturing conditions for three distributions/challenges in 2021 (C1A: May to July, C1B: August to October, and C1C: November to December). Composition and design of the panels followed QCMD’s Code of Practice and ISO 17043 requirements for proficiency testing. The panels included five or six samples containing preparations from inactivated SARS-CoV-2-positive supernatants of various strains (including variants of concern, VOs) at different concentrations, or negative samples with either stabilisation buffer (virus-sPHIX-P9\(^{19}\), RNAssist, Cambridge, UK) or transport medium (proprietary recipe) only, the latter was chosen as the standard matrix for the EQA scheme.

SARS-CoV-2 supernatants from Vero cell culture were purified by centrifugation at 300 \(\times\) G for 10 min, then inactivated chemically (0.05% \(\beta\)-propiolactone; 14 h at 4 °C, and then 2 h incubation at 37 °C) followed by gamma-irradiation (30 kGy). SARS-CoV-2 strains/variants were obtained from the Charité-Universitätsmedizin Berlin Institute of Virology including the Lineage B.1 strain BetaCoV/Munich/ChVir984/2020 (GeneBank accession number: MT270112) from the first reported cluster of COVID-19 cases in Europe January 2020 [16], and the Alpha variant (VOC B.1.1.7) BetaCoV/Passau/ChVir21652/2020 (GISAID accession ID: EPI_ISL_802995).

SARS-CoV-2 strains/variants provided by the Great Romanga Area Hub Laboratory comprised the Delta variant (VOC B.1.617.2) hCoV-19/Italy/EMR-UOM-PVS\(_{C040}\)-21-32/2021 (GISAID: EPI_ISL_7236103), and a B.1.1.7-like Alpha N mutant strain with a 6-nucleotide deletion P207-A208del observed in the nucleoprotein gene [17], hCoV-19/Italy/EMR-UOM-PVS\(_{C040}\)-21-33/2021 (GISAID:EPI_ISL_7236240).

2.2. Quality control of sample preparation

The samples were quantified by different orthogonal droplet digital PCR (ddPCR) reference assays targeting the E (envelope), N (nucleocapsid) and RdRP (RNA-dependant RNA polymerase) gene regions of SARS-CoV-2 (modified from [18]). Prior to distribution to participants, sample preparations were independently tested by six qualified laboratories using a range of different antigen tests confirming the samples were suitable for the EQA, including five LFTs: Abbott - Panbio COVID-19 Ag Rapid Test, Acon Biotech - Flowflex SARS-CoV-2 Antigen Rapid Test, BIOSYNEX - COVID-19 Ag BSS, Roche - SARS-CoV-2 Rapid Antigen Test, Siemens Healthineers - CLINITEST Rapid COVID-19 Antigen Test; one automated PoC test: LumiraDx - SARS-CoV-2 Ag Test; and a chemiluminescence immunoassay-based test: DiaSorin - LIASON SARS-CoV-2 Ag.

2.3. Distribution of panels and EQA testing

EQA panels were distributed under ambient conditions as liquid samples to registered participants with instructions on how to process the samples and submit results. Participants were asked to test and test the material according to their routine testing protocol. Therefore, ‘swab-based testing’ (by placing a swab into the sample) or ‘liquid sample-based testing’ (by pipetting a specified volume of the sample into an assay buffer) were allowed in accordance with manufacturer instructions. Upon completion of the EQA testing, participants could report their results (‘positive’, ‘negative’, or ‘not determined’) using a result return form, either accessible via a mobile device by scanning a QR code provided with the panel, or via the QCMD website (www.qcmd.org). Workflow details were collected as part of the results submission. Participants were also surveyed to provide information about their organisation type and organisations accreditation status.

2.4. Analysis of results from participants

Each submission using the result return form was considered to be a dataset for an individual antigen test method (workflow) together with the reported results for each sample. The use of multiple assays was recorded on separate forms. For this EQA scheme, qualitative results were evaluated. The assessment focussed on sensitivity of workflows at relevant viral loads (i.e., at least 6.4 ddPCR log\(_{10}\) copies/mL). However, the impact of circulating SARS-CoV-2 strains/variants was also taken into consideration.

Overall performance was determined by comparison of results against the EQA consensus. Where there were sufficient datasets available (\(\geq 5\) datasets), the testing methods used were grouped to generate a specific method assessment group consensus. All participants received an EQA report with individual performance and peer group assessment on completion of a challenge.

Participants were expected to report the ‘core’ proficiency samples correctly within the EQA scheme (i.e., all SARS-CoV-2-positive samples with a viral load of 6.4 ddPCR log\(_{10}\) copies/mL as well as the negative control in transport medium for challenges C1A to C1C, and further the SARS-CoV-2-positive sample with 7.4 ddPCR log\(_{10}\) copies/mL as well as the negative control in stabilisation buffer for challenge C1A).

Furthermore, during the testing process prior to distribution to participants it was demonstrated that the number of positive tests decreased at a concentration of 6.4 ddPCR log\(_{10}\) copies/mL, indicating the observable cut-off for LFTs (data not shown). Educational samples with lower concentration for the different matrix types were included in the panels to further determine the sensitivity within a wider range of different testing methods without disadvantaging the performance assessment for participants.

2.5. Statistical analyses

Test performance data was displayed with the frequencies and percentage of correct results. Binary logistic regression models were applied using a correct answer as the response variable. Odds ratios (ORs), their two-sided Wald 95% confidence intervals and \(p\)-values when testing against an OR of 1 were shown. For comparison across or within technologies, the ORs were adjusted for strains/variants. All analyses were performed using the statistical software package SAS version 9.4. (SAS Institute Inc., Cary, USA).

3. Results

In this EQA study, 197 participants from 27 countries worldwide (Fig. 1) took part in at least one of the three challenges (C1A, C1B, C1C). Notably, most participants were from Zambia (\(n = 89\)) as laboratories were enrolled by their public health authority, followed by participants from Great Britain (\(n = 32\)), Poland (\(n = 22\)), and Italy (\(n = 12\)). The remaining were from other countries and/or regions. As participants could register for each individual challenge in any combination, in total 258 respondents (77 in C1A, 138 in C1B, and 43 in C1C) were counted submitting 472 datasets (Table 1). Multiple datasets were reported by 42 respondents for the same assay or combination of different assays or technologies. Fig. 1 shows the proportions of participants and their
During the results submission, in total 200 testing sites have been reported for which the absolute numbers are depicted in Fig. 2. Most of the testing sites were microbiology laboratories (n = 152, 76.0%), followed by non-laboratory organisations (n = 41, 20.5%) and test manufacturers (n = 7, 3.5%). Furthermore, of these, 49 (24.5%) have an accredited or certified quality management system (including regional requirements for four testing sites), 25 (12.5%) are pending accreditation (for ISO 15189/ISO 22870, or ISO 17025); 42 (21.0%) are not accredited or certified, five (2.5%) indicate that they don’t require accreditation/certification, and 79 (39.5%) didn’t provide specific information for the survey. No remarkable difference in the performances between ‘laboratory testing sites’ and ‘non-laboratory testing sites’ (excluding test manufacturers) were observed with 94.3% versus 94.5% overall percentage of correct reported results (p = 0.1479), respectively. However, it must be noted that the non-laboratory testing sites in this study were mostly run by testing professionals or were linked to clinical or diagnostic laboratories.

All core samples were correctly reported by 83.1% (64/77) of the participants and in 83.2% (119/143) of datasets for challenge C1A (correct range per core sample: 89.5–96.5%, Table 1); in 82.6% (114/138) at participant level and 83.8% (181/216) at dataset level within

**Table 1**

QCMD 2021 SARS-CoV-2 Antigen Testing EQA Study - Composition of panels and overall performance per sample.

| Challenge C1A (May to Jul 2021) | Sample code | Sample content | Matrix | Viral RNA concentration (ddPCR log_{10} copies/mL) | Sample status | Percentage correct qualitative results (all) % | Total datasets |
|---------------------------------|-------------|----------------|--------|---------------------------------|---------------|---------------------------------|--------------|
| SCV2Ag21C1A-01                  | SARS-CoV-2 Lineage B.1 | Stabilisation buffer | 6.4 | Educational | 66.4 | 143 |
| SCV2Ag21C1A-02                  | SARS-CoV-2 Lineage B.1 | Stabilisation buffer | 7.4 | Core | 89.5 | 143 |
| SCV2Ag21C1A-03                  | True Negative | Stabilisation buffer | N/A | Core | 90.2 | 143 |
| SCV2Ag21C1A-04                  | SARS-CoV-2 Lineage B.1 | Transport medium | 6.4 | Core | 96.5 | 143 |
| SCV2Ag21C1A-05                  | SARS-CoV-2 Lineage B.1 | Transport medium | 5.4 | Educational | 32.9 | 143 |
| Challenge C1B (Aug to Oct 2021) | Sample code | Sample content | Matrix | Viral RNA concentration (ddPCR log_{10} copies/mL) | Sample status | Percentage correct qualitative results (all) % | Total datasets |
| SCV2Ag21C1B-01                  | SARS-CoV-2 Delta variant | Transport medium | 6.4 | Core | 98.1 | 216 |
| SCV2Ag21C1B-02                  | SARS-CoV-2 Lineage B.1 | Stabilisation buffer | 6.4 | Educational | 43.5 | 216 |
| SCV2Ag21C1B-03                  | SARS-CoV-2 Delta variant | Transport medium | 5.4 | Educational | 53.2 | 216 |
| SCV2Ag21C1B-04                  | SARS-CoV-2 Alpha variant | Transport medium | 6.4 | Core | 98.6 | 216 |
| SCV2Ag21C1B-05                  | SARS-CoV-2 Alpha N | Transport medium | 6.4 | Core | 85.6 | 216 |
| SCV2Ag21C1B-06                  | SARS-CoV-2 Lineage B.1 | Transport medium | 6.4 | Core | 94.4 | 216 |
| Challenge C1C (Nov to Dec 2021) | Sample code | Sample content | Matrix | Viral RNA concentration (ddPCR log_{10} copies/mL) | Sample status | Percentage correct qualitative results (all) % | Total datasets |
| SCV2Ag21C1C-01                  | SARS-CoV-2 Alpha variant | Transport medium | 6.4 | Core | 96.5 | 113 |
| SCV2Ag21C1C-02                  | True Negative | Transport medium | N/A | Core | 95.6 | 113 |
| SCV2Ag21C1C-03                  | SARS-CoV-2 Delta variant | Transport medium | 6.4 | Core | 100 | 113 |
| SCV2Ag21C1C-04                  | SARS-CoV-2 Lineage B.1 | Transport medium | 6.4 | Core | 98.2 | 113 |
| SCV2Ag21C1C-05                  | SARS-CoV-2 Alpha N | Transport medium | 6.4 | Core | 77.9 | 113 |

Viral RNA concentrations quantified with ddPCR E gene reference assay (modified from [18]).

N/A: not applicable.
challenge C1B (correct range per core sample: 85.6–98.6%, Table 1); and by 76.7% (33/43) of the participants and in 73.5% (83/113) of the datasets for challenge C1C (correct range per core sample: 77.9–100%, Table 1). The overall false negative rates (including not determined results) were 10.5% (15/143 datasets) in C1A, 7.4% (16/216 datasets) in C1B, and 5.3% (6/113 datasets) in C1C for all core positive samples with the SARS-CoV-2 Lineage B1, Alpha variant or Delta variant. When considering the results for the core positive samples with the Alpha N mutant strain, the overall false negative rates (including not determined results) increased to 16.2% (35/216 datasets) for challenge C1B and to 22.1% (25/113 datasets) for challenge C1C. For core negative samples, the overall false positive rates (including not determined results) were 9.8% (14/143 datasets) in C1A and 4.4% (5/113 datasets) in C1C.

For viral concentration in SARS-CoV-2 positive samples (in stabilization buffer as well as transport medium), the performance comparison against the results for a viral load of 7.4 ddPCR log_{10} copies/mL as reference level shows that the percentage of correct reported results for samples with a viral load of 6.4 ddPCR log_{10} copies/mL were not significantly different (p = 0.2328), but significantly lower in case of 5.4 ddPCR log_{10} copies/mL (p < 0.0001). This viral load dependency agrees with results from the pre-testing process of the EQA scheme (data not shown).

For SARS-CoV-2 strains/variants in core samples with transport medium as standard matrix, compared to the results reported for the SARS-CoV-2 Lineage B1 strain as reference, the proportion of correctly reported results for the Alpha variant was not significantly different, but higher for the Delta variant (p = 0.0272) and lower for the Alpha N mutant strain (p < 0.0001). The last observation clearly shows that deletions in the N gene might have an impact on the performance and increase the risk of false-negative tests.

In total, 32 LFTs, seven PoC platforms and four laboratory ELISA/immunoassay tests were used by the participants within the three EQA challenges. Supplementary Table S1 provides an overview of the assays with their respective number of datasets per challenge and grouped in corresponding method groups (specific method groups were assigned for assays with ≥5 datasets in all three challenges). All reported antigen tests target the N protein, except the tests provided by one manufacturer (Wuhan Life Origin Biotech Joint Stock) for which information was not available. However, in most of the cases the number of reported workflow datasets per assay is too limited to provide here strong statements on the performance for individual assays. The overall percentage of correct reported results ranged between 88.9 and 97.7% for the evaluated method groups in Supplementary Table S1, for all core samples in transport medium.

When comparing all technologies, the adjusted odds ratio for LFTs relative to automated PoC test platforms is significantly less than 1 [OR = 0.405, 95% confidence interval (0.227 - 0.723); p = 0.002], consistent with a lower observed percentage of correct results for the former. In comparison, laboratory ELISA/immunoassay tests have OR = 0.626, 95% confidence interval (0.133 - 2.943); p = 0.553. The observation for LFTs correlates with a higher rate of false negatives in comparison with the other technologies (p = 0.002 when including the results for the Alpha N mutant strain in the statistical analyses; p = 0.0145 excluding the Alpha N results from the analyses).

4. Discussion

This study provides a comparative performance evaluation of available antigen tests as applied by different users. The overall qualitative performance of participants was at an acceptable level within the three challenges and showed comparable success rates to our first EQA scheme for SARS-CoV-2 molecular detection in 2020 [19]. The study objective was the establishment of a new EQA programme for SARS-CoV-2 antigen detection to support testing infrastructures with high-quality proficiency testing options in line with the expansion of testing capabilities during the ongoing pandemic. Continuous monitoring improves quality within testing sites by assessing the performance of antigen tests in routine use.

It should be noted that the panels offered here focused on the sensitivity aspect (viral loads >10^6 copies/mL as acceptable limit of detection for LFTs [20]) with the impact of circulating SARS-CoV-2 strains/variants taken into consideration (as required for in vitro diagnostic products [21]). The performance on specificity, thus false-positive results due to cross-reactivity with other human coronaviruses or respiratory viruses was not specifically assessed within the study but may be included in future panels if applicable. Also, the number of negative samples was limited and may not be as representative as the conclusions presented for the SARS-CoV-2 positive samples that compare a wider peer group.

The EQA challenges showed that sensitivity and false-positivity in relation to true negative samples remained variable for individual methods. Workflows that did not correctly identify one or more of the
core positive samples with SARS-CoV-2 Lineage B1, Alpha variant or Delta variant (emerging worldwide during 2020/2021 [22]), can result in misdiagnoses of infectious cases even with high viral loads. As antigen tests are generally less sensitive compared to molecular tests, where a negative result is returned, it is recommended to exclude an infection by NAAT if a person is suspected to have COVID-19.

Compared to other technologies used in this study, LFTs showed in general a higher rate of false negatives. A recent manufacturer-independent review of a total of 122 CE-marked antigen rapid tests revealed much of this can depend on the test itself, as one in five tests failed the minimum sensitivity of 75% for panel specimens with a quantification cycle (Cq) value ≤25 [15]. In addition to the viral load (as also proven in our study), intrinsic factors of antigen tests (i.e., test sensitivity/specificity), the testing process (e.g., using a swab or pipetting the sample) or the visual interpretation of test results (if a read-out device is not used) may have an influence on the performance and results. Results could therefore vary amongst participants even when the same test has been used. This becomes apparent when results have been accompanied by comments like ‘faint test line’ or ‘weak positive’, indicating that training of users for visual interpretation is important for reliable detection.

The results for the Alpha N mutant strain showed that visual interpretation of LFTs was quite challenging and some automated PoC platforms revealed in certain cases that the performance was also reduced, although all laboratory ELISA/immunoassays tests could detect this mutant strain. While it is assumed that there would be less impact on antigen tests by VOCs than there would be for molecular tests as most of the variants (including Omicron) contain mutations mainly in the S (spike) gene resulting in the observed S gene drop out in particular molecular assays [23], this observation highlights the importance to continuous monitoring for the potential impact of circulating variants and strains through EQA studies for antigen tests where data is still limited.

It is remarkable that only 37% of the participating testing sites reported to be accredited/certified or are pending accreditation. Although we could not show a remarkable difference of the performances between laboratory testing sites and non-laboratory testing sites, quality assurance is an important aspect and regional requirements for antigen testing can vary for users who are no longer limited to laboratory and testing professionals.

Regular participation in EQAs can help to verify if samples are handled properly, results are interpreted correctly, and procedures are followed. EQA schemes can provide valuable data to inform participants about weaknesses in their testing process or methods and support ongoing assay evaluations for regulatory approval or post-market surveillance, which is of particular importance during the pandemic where data about the relative performance of assays and independent extensive comparative evaluations are continuously required. As we are moving to a new phase of the pandemic, a single variant like Omicron with multiple descendant lineages dominates the COVID-19 surge worldwide. To keep the EQA schemes state of art design based on the latest epidemiological information available, for example inclusion of this and further relevant variants/strains in future schemes is of importance. This allows the quality of COVID-19 diagnostic testing to be continuously improved and ensured.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declaration of Competing Interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

We are greatly indebted to all our colleagues who participated in the first QCMD SARS-CoV-2 Antigen Testing EQA Study. We thank Alastair Ricketts and his team (Qnostics Ltd., Glasgow, Scotland) for contributing to the material assessment. Special thanks to the Medische Biologisch Laboratorium at the Diakonessenhuis Hospital, Utrecht, The Netherlands for providing valuable testing results by laboratory ELISA/immunoassay test. We further thank Harry Staines (Sigma Statistical Services, Balmullo, UK) for supporting and reviewing the statistical analyses, and Matthias Niedrig (WHO consultant, Berlin, Germany) for critically reading the manuscript.

Appendix A. Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.jcv.2022.105222.

References

[1] World Health Organization (WHO), Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays, Interim Guidance (2020) [updated 06 October 2021], https://www.who.int/publications/i/item/antigen-detection-in-th treatment-diagnosis-of-sars-cov-2-infection-using-rapid-immunoassays, Accessed 09 February 2022.
[2] European Centre for Disease Prevention and Control (ECDC), Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and the UK. Technical Report, 2020 [updated 26 October 2021], https://www.ecdc.europa.eu/en/publications-data/options-use-rapid-antigen-tests-covid-19-eueea-first-update, Accessed 09 February 2022.
[3] US Centers for Disease Control and Prevention (CDC), Interim guidance for antigen testing for SARS-CoV-2, Interim Guidance (2020) [updated 20 January 2022], https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html, Accessed 09 February 2022.
[4] J. Guo, J. Ge, Y. Guo, Recent advances in methods for the diagnosis of Coronavirus Disease 2019, J. Clin. Lab. Anal. 36 (2022) e214798.
[5] World Health Organization (WHO), Recommendations for national SARS-CoV-2 testing strategies and diagnostic capacities, Interim Guidance (2021), https://www.who.int/publications/i/item/WHO-2019-nCoV-lab-testing-2021.1-eng, Accessed 12 January 2022.
[6] T. Toptan, L. Eckermann, A.E. Pfeiffer, S. Hoehl, S. Ciesek, C. Drosten, et al., Evaluation of a SARS-CoV-2 rapid antigen test: potential to help reduce community spread? J. Clin. Virol. 135 (2021), 104713.
[7] A. Cruzier, S. Rajan, I. Buchan, M. McKee, Put to the test: use of rapid testing technologies for covid-19, BMJ 372 (2021) n208.
[8] S. Ricks, E.A. Kendall, D.W. Dowdy, J.A. Sacks, S.G. Schumacher, N. al-Mamum, Quantifying the potential value of antigen-detection rapid diagnostic tests for COVID-19: a modelling analysis, BMC Med. 19 (2021) 75.
[9] I. Wagenhauer, K. Knes, V. Rauschenberger, M. Eisenmann, M. McDonogh, N. Petri, et al., Clinical performance evaluation of SARS-CoV-2 rapid antigen testing in point of care usage in comparison to RT-qPCR, ElifeMed. 69 (2021), 103455.
[10] V. Martín-Sánchez, T. Fernandez-Villa, A. Carvajal Urueña, A. Rivero Rodríguez, S. Regueiro Celada, G. Sánchez Antolin, et al., Role of Rapid Antigen Testing in Population-Based SARS-CoV-2 Screening, J. Clin. Med. 10 (2021) 3845.
[11] Foundation for Innovative New Diagnostics (FIND), SARS-CoV-2 Diagnostic Pipeline, https://www.finddx.org/covid-19/pipeline/?test_target=Antigen&status=all&section=show-all&section=default, 2022. Accessed 09 February 2022.
[12] Joint Research Centre of the European Commission (JRC), COVID-19 in vitro diagnostic devices and test methods database, https://covid-19-diagnostics.jrc.ec.europa.eu/, 2022. Accessed 09 February 2022.
[13] J. Dinnes, J.J. Derks, S. Berhane, M. Adriano, C. Davenport, et al., Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection (Review), Cochrane Database Syst. Rev. 3 (2021), CD013705.
[14] L.E. Brümmer, S. Katzenschlager, M. Gaedert, C. Erdmann, S. Schmitz, M. Bota, et al., Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: a living systematic review and meta-analysis, PLoS Med. 18 (2021), e1003735.
[15] H. Schreiblauer, A. Filomena, A. Nitsche, A. Puyskens, V.M. Gorman, C. Drosten, et al., Comparative sensitivity evaluation of 122 CE-marked rapid diagnostic tests for SARS-CoV-2 antigen, Germany, Euro Surveill 26 (2021), 2100411.
[16] M.M. Ebnner, U. Buchholz, V.M. Gorman, M. Hoeh, K. Kertz, D.V. Marosevic, et al., Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series, Lancet Infect. Dis. 20 (2020) 920–928.
[17] S. Zanzoli, G. Drir, F. Taddei, G. Gatti, I. Poggianti, A. Denicolo, et al., A deletion in the N gene may cause diagnostic escape in SARS-CoV-2 samples, Diagn. Microbiol. Infect. Dis. 102 (2022), 115540.
[18] V.M. Gorman, O. Landt, M. Kaiser, R. Molenkamp, A. Meijer, D.W. Chu, et al., Detection of 2019 novel coronavirus (2019-ncov) by real-time RT-PCR, Euro Surveill. 25 (2020), 2000045.
[19] V. Matheeussen, V.M. Corman, O. Donoso Mantke, E. McCulloch, C. Lammens, H. Goossens, et al., International external quality assessment for SARS-CoV-2 molecular detection and survey on clinical laboratory preparedness during the COVID-19 pandemic, April/May 2020, Euro Surveill 25 (2020), 2001223.

[20] World Health Organization (WHO), Target product profiles for priority diagnostics to support response to the COVID-19 pandemic v.1.0. R&D Blueprint, 2020. https://www.who.int/publications/m/item/covid-19-target-product-profiles-for-priority-diagnostics-to-support-response-to-the-covid-19-pandemic-v.0.1. Accessed 31 January 2022.

[21] Medical Device Coordination Group (MDCG), MDCG 2021-21 Guidance on performance evaluation of SARS-CoV-2 in vitro diagnostic medical devices, Guidance Document (2021). https://ec.europa.eu/health/system/files/2021-08/mdcg_2021-21_en_0.pdf. Accessed 31 January 2022.

[22] CoVariants (enabled by data from GISAID), Overview of Variants in Countries. https://covariants.org/per-country, 2020-2022. Accessed 02 February 2022.

[23] Foundation for Innovative New Diagnostics (FIND), Impact OF VARIANTS on COVID-19 Tests. https://www.finddx.org/covid-19/impact-of-variants-on-covid-19-tests/, 2022. Accessed 02 February 2022.